Ovarian cancer combo trial halted early

NCT ID NCT02389985

Terminated Disease control Sponsor: NewLink Genetics Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug, CRLX101, combined with standard chemotherapy (paclitaxel) in 30 women with ovarian cancer that came back or didn't go away. The goal was to find the safest dose and see if the combination helped shrink tumors. The trial was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Show contact details

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
The Ohio State University

Columbus, Ohio, 43210, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Oklahoma / Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
University of Virginia Health System

Charlottesville, Virginia, 22901, United States
Washington University

St Louis, Missouri, 63110, United States
Women & Infants Hospital of Rhode Island

Providence, Rhode Island, 02095, United States